28.99  -0.23 (-0.79%)		12-30 12:06
Open: 29.285 High: 29.285 Volume: 537,584		Pre. Close: 29.22 Low: 28.95 Market Cap: 938(M)

Short term
Mid term
Targets	6-month :	35.96	1-year :	37.34
Resists	First :	30.79	Second :	31.96
Pivot price	29.93
Supports	First :	28.88	Second :	24.03
MAs	MA(5) :	29.64	MA(20) :	30.18
	MA(100) :	28.37	MA(250) :	0
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	14.5	D(3) :	26
RSI	RSI(14): 43.9
52-week	High :	34.06	Low :	17.5

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ARKG ] has closed above bottom band by 16.9%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	29.82 - 30	30 - 30.13
Low:	28.64 - 28.88	28.88 - 29.04
Close:	28.92 - 29.26	29.26 - 29.49

The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Fri, 26 Dec 2025
Cathie Wood Bets Big On Self-Driving and Gene-Editing Stocks Ahead of 2026 - TradingView — Track All Markets

Tue, 23 Dec 2025
Noteworthy ETF Outflows: ARKG, TEM, TWST, GH - Nasdaq

Fri, 12 Dec 2025
Precision Trading with Ark Genomic Revolution Etf (ARKG) Risk Zones - Stock Traders Daily

Thu, 11 Dec 2025
Pacific Biosciences: What happens with this penny stock? - FXStreet

Sun, 26 Oct 2025
StockWatch: Top 3 Biotech ETFs Finally Bounce Back with the Market - Genetic Engineering and Biotechnology News

Tue, 07 Oct 2025
ARKG: Investing In The Genomics Revolution (BATS:ARKG) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: CBOE
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.